G J Gorse

Summary

Affiliation: Saint Louis University
Country: USA

Publications

  1. ncbi request reprint Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial
    Geoffrey J Gorse
    Saint Louis Veterans Affairs Medical Center and St Louis University School of Medicine, St Louis, MO, USA
    Vaccine 24:5950-9. 2006
  2. doi request reprint Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age
    Geoffrey J Gorse
    Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, 1100 S Grand Boulevard, St Louis, MO 63104, USA Electronic address
    Vaccine 31:6034-40. 2013
  3. doi request reprint Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age
    Geoffrey J Gorse
    Saint Louis University School of Medicine, 1100 South Grand Blvd DRC 8th floor, St Louis, MO 63104, USA
    Vaccine 31:2358-65. 2013
  4. pmc DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults
    Geoffrey J Gorse
    Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, School of Medicine, Saint Louis University, St Louis, Missouri, USA
    Clin Vaccine Immunol 19:649-58. 2012
  5. pmc Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum
    Geoffrey J Gorse
    Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, 1100 South Grand Boulevard, St Louis, MO 63104, USA
    Clin Vaccine Immunol 17:1875-80. 2010
  6. doi request reprint Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center, St Louis, Missouri, USA
    J Infect Dis 199:847-57. 2009
  7. ncbi request reprint Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Saint Louis University, St Louis, MO 63104, United States
    Vaccine 26:215-23. 2008
  8. ncbi request reprint Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination
    Geoffrey J Gorse
    Division of Infectious Diseases and Immunology, Saint Louis University Health Sciences Center, 3635 Vista Ave FDT 8N, St Louis, MO 63110, USA
    Chest 130:1109-16. 2006
  9. pmc Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1
    Geoffrey J Gorse
    Division of Infectious Diseases and Immunology, Saint Louis University Health Sciences Center, School of Medicine, 3635 Vista Ave FDT 8N, St Louis, MO 63110, USA
    Clin Vaccine Immunol 13:26-32. 2006
  10. ncbi request reprint Immunity to influenza in older adults with chronic obstructive pulmonary disease
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 190:11-9. 2004

Detail Information

Publications23

  1. ncbi request reprint Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial
    Geoffrey J Gorse
    Saint Louis Veterans Affairs Medical Center and St Louis University School of Medicine, St Louis, MO, USA
    Vaccine 24:5950-9. 2006
    ..We report the results of a phase I dose escalation, safety and immunogenicity trial of a new recombinant protective antigen (rPA102) anthrax vaccine...
  2. doi request reprint Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age
    Geoffrey J Gorse
    Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, 1100 S Grand Boulevard, St Louis, MO 63104, USA Electronic address
    Vaccine 31:6034-40. 2013
    ....
  3. doi request reprint Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age
    Geoffrey J Gorse
    Saint Louis University School of Medicine, 1100 South Grand Blvd DRC 8th floor, St Louis, MO 63104, USA
    Vaccine 31:2358-65. 2013
    ..To increase vaccine acceptance, intradermal (ID) influenza vaccine (Fluzone(®) Intradermal, Sanofi Pasteur Inc.) may be an attractive alternative to intramuscular (IM) vaccination due to smaller needle and volume injected...
  4. pmc DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults
    Geoffrey J Gorse
    Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, School of Medicine, Saint Louis University, St Louis, Missouri, USA
    Clin Vaccine Immunol 19:649-58. 2012
    ..These peptide-based vaccines were safe but were ineffective at inducing HIV-1-specific immune responses and induced much weaker responses than MVA vaccines expressing the entire open reading frames of HIV-1 proteins...
  5. pmc Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum
    Geoffrey J Gorse
    Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, 1100 South Grand Boulevard, St Louis, MO 63104, USA
    Clin Vaccine Immunol 17:1875-80. 2010
    ..Patients likely had experienced infections with more than one HCoV strain, and IgG antibodies to these HCoV strains in serum were more likely to be detected than IgA antibodies to these HCoV strains in nasal wash specimens...
  6. doi request reprint Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center, St Louis, Missouri, USA
    J Infect Dis 199:847-57. 2009
    ..The clinical features and incidence of human coronavirus (HCoV) infections in chronically ill older adults need better definition...
  7. ncbi request reprint Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Saint Louis University, St Louis, MO 63104, United States
    Vaccine 26:215-23. 2008
    ..Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic...
  8. ncbi request reprint Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination
    Geoffrey J Gorse
    Division of Infectious Diseases and Immunology, Saint Louis University Health Sciences Center, 3635 Vista Ave FDT 8N, St Louis, MO 63110, USA
    Chest 130:1109-16. 2006
    ....
  9. pmc Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1
    Geoffrey J Gorse
    Division of Infectious Diseases and Immunology, Saint Louis University Health Sciences Center, School of Medicine, 3635 Vista Ave FDT 8N, St Louis, MO 63110, USA
    Clin Vaccine Immunol 13:26-32. 2006
    ..05). Increased CMI responses to HIV-1 envelope glycoprotein measured by lymphocyte proliferation were associated with HIV-1 recombinant envelope glycoprotein vaccines...
  10. ncbi request reprint Immunity to influenza in older adults with chronic obstructive pulmonary disease
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Division of Infectious Diseases and Immunology, Saint Louis University, St Louis, Missouri, USA
    J Infect Dis 190:11-9. 2004
    ..Chronically ill older adults constitute a population vulnerable for complications associated with influenza. Study of their immunity to influenza virus may help design better strategies to stimulate protective immune responses...
  11. ncbi request reprint Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection
    Geoffrey J Gorse
    St Louis Department of Veterans Affairs Medical Center, St Louis University, St Louis, MO 63110, USA
    Vaccine 22:383-97. 2004
    ..Sera from vaccine recipients bound to HIV-1-infected cells, but at levels lower than did infected patient sera...
  12. ncbi request reprint Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study
    Geoffrey J Gorse
    Department of Veterans Affairs, Medical Center, Saint Louis University, St Louis, MO, USA
    Vaccine 21:2133-44. 2003
    ..17, 0.53), and -0.05 for type B virus (95% CL: -1.13, 0.48). However, there was a possible advantage for TC over TP in reducing respiratory consequences of an influenza season measured by pulmonary function and symptoms at end of study...
  13. ncbi request reprint Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
    G J Gorse
    St Louis Department of Veterans Affairs Medical Center, St Louis, MO, USA
    Vaccine 18:835-49. 1999
    ..Canarypox virus-based HIV-1 vaccines represent a step forward in HIV-1 vaccine development...
  14. ncbi request reprint Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120
    G J Gorse
    St Louis Department of Veterans Affairs Medical Center, and Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, 3635 Vista Avenue FDT 8N, St Louis, MO 63110, USA
    Vaccine 19:1806-19. 2001
    ..Hence, vCP205 and SF-2 rgp120 subunit vaccines given together and in a prime-boost sequence appeared to induce a broader cytokine response pattern than vCP205 vaccine given alone...
  15. ncbi request reprint HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers
    G J Gorse
    St Louis Department of Veterans Affairs Medical Center, St Louis, Missouri 63106, USA
    AIDS Res Hum Retroviruses 17:1175-89. 2001
    ..Thus, a durable anti-HIV-1 CD8(+) CTL response was detected after immunization with the live canarypox virus vaccine and preexisting helper T cell memory responses did not necessarily predict later CD8(+) CTL activity...
  16. ncbi request reprint Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers
    R B Belshe
    Department of Internal Medicine, Saint Louis University School of Medicine and St Louis Veterans Affairs Medical Center, 3635 Vista Ave FDT 8N St Louis, MO 63110, USA
    J Infect Dis 183:1343-52. 2001
    ....
  17. ncbi request reprint Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production
    S Worku
    Division of Infectious Diseases and Immunology, Department of Internal Medicine, Saint Louis University Health Sciences Center, St Louis, Missouri, USA
    J Infect Dis 184:525-32. 2001
    ..02). Increased IFN-gamma production by gammadelta T and NK cells could enhance the induction of protective type 1 memory immunity. Thus, stimulation of gammadelta T cells might be an important feature of live vaccines...
  18. ncbi request reprint MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group
    G J Gorse
    St Louis Department of Veterans Affairs Medical Center and Saint Louis University School of Medicine, Missouri 63110, USA
    AIDS Res Hum Retroviruses 15:921-30. 1999
    ..We conclude that MN rgp120 HIV-1 vaccine was an effective inducer of antibody to native envelope glycoproteins of antigenically diverse primary isolates of HIV-1...
  19. ncbi request reprint Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein
    Peter F Wright
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Infect Dis 189:1221-31. 2004
    ....
  20. ncbi request reprint Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
    Kalpana Gupta
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Acquir Immune Defic Syndr 29:254-61. 2002
    ..This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers...
  21. ncbi request reprint Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine
    Kathleen M Neuzil
    Department of Veterans Affairs Puget Sound Health Care System and University of Washington School of Medicine, Seattle, Washington 98108, USA
    Clin Infect Dis 36:169-74. 2003
    ..Additional studies are warranted to define optimal methods for the diagnosis of influenza among older persons with chronic obstructive pulmonary disease...
  22. ncbi request reprint Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial
    Clayton D Harro
    The Johns Hopkins Bloomberg School of Public Health, Center for Immunization Research, Baltimore, Maryland 21205, USA
    J Acquir Immune Defic Syndr 37:1385-92. 2004
    ..To describe recruitment and baseline epidemiologic characteristics of volunteers in the first phase 3 placebo-controlled trial of a recombinant gp120 HIV vaccine (AIDSVAX B/B)...
  23. ncbi request reprint Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7"
    Geoffrey J Gorse
    Vaccine 25:7285-7. 2007